Orchard Therapeutics

Overview

Biotech company that continued GSK's rare disease gene therapy programs before discontinuing commercialization of the ADA-SCID therapy for commercial reasons, prompting Fondazione Telethon to take over the license. Orchard Therapeutics continued GSK's rare disease gene therapy work through a true knowledge-exchange collaboration, but subsequently discontinued commercialization of the ADA-SCID therapy for purely commercial reasons despite it being an approved product administered to patients from multiple countries. (Segment 1-2 (00:00-10:00))